• SPONTAN® pharmacy distribution commenced through Symbion network
• ROXUS® development milestones achieved, on track for US launch in H1 2026
• OROFLOW® development agreement signed for novel intranasal treatment targeting Oesophageal Motility Disorders

LTR Pharma Limited (ASX:LTP), a company focused on developing innovative nasal spray treatments for erectile dysfunction and other therapeutic areas, provided an update on its activities and financial results for the quarter ended 30 June 2025. Key highlights include the commencement of SPONTAN® pharmacy distribution through the Symbion network, continued progress on ROXUS® development with plans for a US launch in H1 2026, and the signing of a collaborative agreement to develop OROFLOW® for Oesophageal Motility Disorders. The company also strengthened its clinical leadership with the appointment of A/Prof. Darren Katz to the Scientific Advisory Board. LTR Pharma maintained a robust financial position with $31.8 million in cash at the end of the quarter, providing substantial runway to execute its strategic objectives. The company remains focused on key priorities for the remainder of 2025, including completing ROXUS® development, expanding SPONTAN® commercial availability, commencing a Phase II pharmacokinetic study, and initiating regulatory engagement for SPONTAN® in the European Union.

LTR Pharma is focused on several key priorities for the remainder of 2025, including: completing ROXUS® development and preparing for US launch in H1 2026, continuing to support SPONTAN® commercial expansion, commencing the Phase II pharmacokinetic study for SPONTAN®, and initiating regulatory engagement for SPONTAN® in the European Union. The company is also pursuing pipeline expansion through the advancement of OROFLOW® and evaluation of new therapeutic indications.